Response assessment using ⁶⁸Ga-PSMA ligand PET in patients undergoing ¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

ABSTRACT:

Purpose

The first aim of this study was to evaluate ⁶⁸Ga-PSMA^HBED-CC conjugate 11 positron emission tomography (PSMA PET) parameters for assessment of response to ¹⁷⁷Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The second aim was to investigate factors associated with overall survival (OS).

Methods

We retrospectively assessed mean standardized uptake values (SUVmean) and total tumor volumes (TTV) on PSMA PET in 38 of 55 mCRPC patients before and after RLT. PSA testing and PSMA PET/CT(MRI) imaging were performed during the 8 weeks before and the 6 weeks after RLT. PSMA PET and CT(MRI) images were reviewed separately according to the modified PET Response Criteria in Solid Tumor

SUBMITTER: Grubmuller B 

PROVIDER: S-EPMC6451716 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature